en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
5/2007
vol. 45
 
Share:
Share:
more
 
 
abstract:

Review article
Treatment of systemic vasculitis – clinical aspects

Justyna Swarowska-Knap
,
Witold Tłustochowicz

Reumatologia 2007; 45, 5: 278-283
Online publish date: 2007/10/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Systemic vasculitis is treatable but not curable. Combination therapy with corticosteroids and immunosuppressives induces remission in approximately 90% of cases. Treatment employing cyclophosphamide and prednisone has improved prognosis, but relapses and treatment-induced side effects still cause severe morbidity and frequent mortality. The optimal doses and duration of the treatment remain to be clarified in the large multicentre randomized trials. Patients with vasculitis should be treated as soon as possible. Treatment should not be delayed until a definitive diagnosis is made. For patients with mild forms of vasculitis, initial therapy with corticosteroids and agents other than cyclophosphamide may be adequate to induce remission. Patients with poor prognostic factors (FFS>0) require therapy with corticosteroids and cyclophosphamide. Usually disease has remitted or markedly improved after 3-6 months and later transition to alternative agents is possible for most patients.
keywords:

vasculitis, cyclophosphamide, anticytoplasmatic neutrophil antibodies







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.